Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Despite recent significant advances in genomic techniques, there are currently no practice guidelines for the clinical implementation of genomics.

The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), in association with researchers at the University of Oxford and the Harvard Stem Cell Institute have today published an Opinion piece in Nature Medicine, which recommends the development of ‘Good Genomic Practice’ (GGP) guidelines. Like good laboratory practice (GLP) and good manufacturing practice (GMP), GGP aims to ‘ensure the quality and consistency of medical research and practice’ in the field.

The proposed guidelines would address the ethical, scientific, quality assurance, data handling and storage issues surrounding genomic diagnosis, setting out best practice principles from ‘initial sample collection to the ultimate clinical decision.

Good practice guidelines in this field would result in greater consistency in the reported results as well as an improved understanding of the clinical significance of genetic variants. Not only is this a step towards stratifying medicine; but also the development of integrated global databases with standardized formats, bringing the ultimate goal of truly personalizing treatments closer.

The authors suggest that international leaders in the genomics field should create a checklist to map out the key stages in the process that require standardization and then work with wider stakeholders to formulate guidelines.  Defining the parameters of GGP at this early stage will ensure that the field realizes its ‘boundless potential to improve human health.’


Links:

Original paper in Nature

CASMI

Similar stories

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

Medical Sciences Division receives REF 2021 results

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021. REF is the UK-wide assessment of research in universities, and provides an expert evaluation of the quality of the research outputs, impact and environment at subject level in each university.